Dr. Jiaqiang Cai, PhDCo-founder, CSO and Co-CEO at MediLink TherapeuticsSpeaker
Profile
Dr. Cai is the Co-founder, CSO and Co-CEO of MediLink Therapeutics. Before cofounding Medilink Therapeutics, Dr. Cai served as vice general manager and director of chemistry of Shanghai Hansoh Pharm. Before joining Hansoh, Dr Cai was deputy general manager of Sichuan Kelun Institute of Pharmaceutical Research responsible for small molecule drug R&D and Kelun’s innovation centre managing over 250 research scientists. Dr. Cai accumulated over 30 years of experience in drug discovery research, managed over 100 projects across different therapeutic areas with 30 compounds in different stages of clinical development, 8 of them are antibody drug conjugates, including SKB264, SKB315, YL201 and YL202. Dr. Cai graduated from Dalian Institute of Chemical Physics with PhD degree, finished post-doctoral training at University College London. Before returning to China, Dr. Cai was senior team leader and project leader at Merck’s (MSD) UK research centre.